LINCS MCF 10A Common Project: Rolling-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 1 of 15: End-point cell counts and normalized growth rate inhibition values for all technical replicates of biological replicate 1. - Dataset (ID:20309)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Time Point (hr) | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value | Assay Plate | Assay Well |
|---|---|---|---|---|---|---|---|---|---|---|
| MCF 10A-H2B-mCherry | Trametinib | 0.017783 | 83.42 | 770.25 | 3023 | 12031 | 0.2513 | 0.4117 | MN20160304_L02 | I05 |
| MCF 10A-H2B-mCherry | Trametinib | 0.017783 | 85.64 | 770.25 | 3182 | 12287 | 0.2590 | 0.4262 | MN20160304_L02 | F03 |
| MCF 10A-H2B-mCherry | Trametinib | 0.017783 | 85.64 | 770.25 | 3091 | 12287 | 0.2516 | 0.4159 | MN20160304_L02 | I05 |
| MCF 10A-H2B-mCherry | Trametinib | 0.017783 | 87.86 | 770.25 | 3274 | 12543 | 0.2610 | 0.4326 | MN20160304_L02 | F03 |
| MCF 10A-H2B-mCherry | Trametinib | 0.017783 | 87.86 | 770.25 | 3153 | 12543 | 0.2514 | 0.4192 | MN20160304_L02 | I05 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 3.21 | 770.25 | 849 | 904 | 0.9385 | 0.5214 | MN20160304_L02 | C04 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 3.21 | 770.25 | 883 | 904 | 0.9761 | 0.8019 | MN20160304_L02 | F10 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 5.44 | 770.25 | 964 | 1012 | 0.9519 | 0.7651 | MN20160304_L02 | C04 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 5.44 | 770.25 | 986 | 1012 | 0.9736 | 0.8689 | MN20160304_L02 | F10 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 7.66 | 770.25 | 1079 | 1090 | 0.9899 | 0.9599 | MN20160304_L02 | C04 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 7.66 | 770.25 | 1051 | 1090 | 0.9642 | 0.8597 | MN20160304_L02 | F10 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 10.06 | 770.25 | 1158 | 1218 | 0.9504 | 0.8519 | MN20160304_L02 | C04 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 10.06 | 770.25 | 1147 | 1218 | 0.9413 | 0.8253 | MN20160304_L02 | F10 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 12.28 | 770.25 | 1270 | 1358 | 0.9351 | 0.8426 | MN20160304_L02 | C04 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 12.28 | 770.25 | 1249 | 1358 | 0.9197 | 0.8054 | MN20160304_L02 | F10 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 14.50 | 770.25 | 1393 | 1497 | 0.9304 | 0.8550 | MN20160304_L02 | C04 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 14.50 | 770.25 | 1353 | 1497 | 0.9037 | 0.7995 | MN20160304_L02 | F10 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 16.73 | 770.25 | 1458 | 1664 | 0.8759 | 0.7754 | MN20160304_L02 | C04 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 16.73 | 770.25 | 1407 | 1664 | 0.8453 | 0.7194 | MN20160304_L02 | F10 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 18.95 | 770.25 | 1479 | 1832 | 0.8071 | 0.6850 | MN20160304_L02 | C04 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 18.95 | 770.25 | 1439 | 1832 | 0.7853 | 0.6484 | MN20160304_L02 | F10 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 21.17 | 770.25 | 1498 | 2008 | 0.7459 | 0.6178 | MN20160304_L02 | C04 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 21.17 | 770.25 | 1425 | 2008 | 0.7095 | 0.5604 | MN20160304_L02 | F10 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 23.39 | 770.25 | 1489 | 2244 | 0.6634 | 0.5329 | MN20160304_L02 | C04 |
| MCF 10A-H2B-mCherry | Trametinib | 0.031623 | 23.39 | 770.25 | 1441 | 2244 | 0.6420 | 0.5007 | MN20160304_L02 | F10 |